These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 36979714)

  • 1. Identification of Kinase Targets for Enhancing the Antitumor Activity of Eribulin in Triple-Negative Breast Cell Lines.
    Xie X; Lee J; Fuson JA; Liu H; Iwase T; Yun K; Margain C; Tripathy D; Ueno NT
    Biomedicines; 2023 Feb; 11(3):. PubMed ID: 36979714
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of Copanlisib in Combination with Eribulin in Triple-negative Breast Cancer Patient-derived Xenograft Models.
    Guo Z; Luo J; Mashl RJ; Hoog J; Maiti P; Fettig N; Davies SR; Aft R; Held JM; Govindan R; Ding L; Li S; von Morze C; Wulf GM; Shoghi KI; Ma CX
    Cancer Res Commun; 2024 Jun; 4(6):1430-1440. PubMed ID: 38717161
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Eribulin Synergistically Increases Anti-Tumor Activity of an mTOR Inhibitor by Inhibiting pAKT/pS6K/pS6 in Triple Negative Breast Cancer.
    Wen W; Marcinkowski E; Luyimbazi D; Luu T; Xing Q; Yan J; Wang Y; Wu J; Guo Y; Tully D; Han ES; Yost SE; Yuan Y; Yim JH
    Cells; 2019 Aug; 8(9):. PubMed ID: 31480338
    [TBL] [Abstract][Full Text] [Related]  

  • 4. TAK228 enhances antitumor activity of eribulin in triple negative breast cancer.
    Owusu-Brackett N; Evans KW; Akcakanat A; Yuca E; Tapia C; Rizvi YQ; Dumbrava EI; Janku F; Meric-Bernstam F
    Oncotarget; 2019 Aug; 10(49):5011-5019. PubMed ID: 31489111
    [No Abstract]   [Full Text] [Related]  

  • 5. PI3K and MAPK Pathways as Targets for Combination with the Pan-HER Irreversible Inhibitor Neratinib in HER2-Positive Breast Cancer and TNBC by Kinome RNAi Screening.
    Lee J; Liu H; Pearson T; Iwase T; Fuson J; Lalani AS; Eli LD; Diala I; Tripathy D; Lim B; Ueno NT
    Biomedicines; 2021 Jun; 9(7):. PubMed ID: 34203351
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PI3K inhibition enhances the anti-tumor effect of eribulin in triple negative breast cancer.
    Rajput S; Guo Z; Li S; Ma CX
    Oncotarget; 2019 Jun; 10(38):3667-3680. PubMed ID: 31217901
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The histone deacetylase inhibitor OBP-801 and eribulin synergistically inhibit the growth of triple-negative breast cancer cells with the suppression of survivin, Bcl-xL, and the MAPK pathway.
    Ono H; Sowa Y; Horinaka M; Iizumi Y; Watanabe M; Morita M; Nishimoto E; Taguchi T; Sakai T
    Breast Cancer Res Treat; 2018 Aug; 171(1):43-52. PubMed ID: 29752686
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combined kinase inhibitors of MEK1/2 and either PI3K or PDGFR are efficacious in intracranial triple-negative breast cancer.
    Van Swearingen AED; Sambade MJ; Siegel MB; Sud S; McNeill RS; Bevill SM; Chen X; Bash RE; Mounsey L; Golitz BT; Santos C; Deal A; Parker JS; Rashid N; Miller CR; Johnson GL; Anders CK
    Neuro Oncol; 2017 Oct; 19(11):1481-1493. PubMed ID: 28486691
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of autophagy by chloroquine prevents resistance to PI3K/AKT inhibitors and potentiates their antitumor effect in combination with paclitaxel in triple negative breast cancer models.
    Cocco S; Leone A; Roca MS; Lombardi R; Piezzo M; Caputo R; Ciardiello C; Costantini S; Bruzzese F; Sisalli MJ; Budillon A; De Laurentiis M
    J Transl Med; 2022 Jun; 20(1):290. PubMed ID: 35761360
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Eribulin Mesylate Improves Cisplatin-Induced Cytotoxicity of Triple-Negative Breast Cancer by Extracellular Signal-Regulated Kinase 1/2 Activation.
    Ko H; Lee M; Cha E; Sul J; Park J; Lee J
    Medicina (Kaunas); 2022 Apr; 58(4):. PubMed ID: 35454385
    [No Abstract]   [Full Text] [Related]  

  • 11. Combination of PI3K and MEK inhibitors yields durable remission in PDX models of PIK3CA-mutated metaplastic breast cancers.
    Coussy F; El Botty R; Lavigne M; Gu C; Fuhrmann L; Briaux A; de Koning L; Dahmani A; Montaudon E; Morisset L; Huguet L; Sourd L; Painsec P; Chateau-Joubert S; Larcher T; Vacher S; Melaabi S; Salomon AV; Marangoni E; Bieche I
    J Hematol Oncol; 2020 Feb; 13(1):13. PubMed ID: 32087759
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting the PI3K/AKT/mTOR Pathway for the Treatment of Mesenchymal Triple-Negative Breast Cancer: Evidence From a Phase 1 Trial of mTOR Inhibition in Combination With Liposomal Doxorubicin and Bevacizumab.
    Basho RK; Gilcrease M; Murthy RK; Helgason T; Karp DD; Meric-Bernstam F; Hess KR; Herbrich SM; Valero V; Albarracin C; Litton JK; Chavez-MacGregor M; Ibrahim NK; Murray JL; Koenig KB; Hong D; Subbiah V; Kurzrock R; Janku F; Moulder SL
    JAMA Oncol; 2017 Apr; 3(4):509-515. PubMed ID: 27893038
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Subtypes of Triple-negative Breast Cancer Cell Lines React Differently to Eribulin Mesylate.
    Bräutigam K; Mitzlaff K; Uebel L; Köster F; Polack S; Pervan M; Steinert G; Rody A; Liedtke C
    Anticancer Res; 2016 Jun; 36(6):2759-66. PubMed ID: 27272786
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Eribulin mesilate suppresses experimental metastasis of breast cancer cells by reversing phenotype from epithelial-mesenchymal transition (EMT) to mesenchymal-epithelial transition (MET) states.
    Yoshida T; Ozawa Y; Kimura T; Sato Y; Kuznetsov G; Xu S; Uesugi M; Agoulnik S; Taylor N; Funahashi Y; Matsui J
    Br J Cancer; 2014 Mar; 110(6):1497-505. PubMed ID: 24569463
    [TBL] [Abstract][Full Text] [Related]  

  • 15. XS-2, a novel potent dual PI3K/mTOR inhibitor, exhibits high in vitro and in vivo anti-breast cancer activity and low toxicity with the potential to inhibit the invasion and migration of triple-negative breast cancer.
    Xu S; Sun X; Luo L; Yang Y; Guo Q; Tang S; Jiang Z; Li Y; Han J; Gan W; Yang F; Zhang X; Liu Y; Sun C; He J; Liu M; Zuo D; Zhu W; Wu Y
    Biomed Pharmacother; 2022 Nov; 155():113537. PubMed ID: 36113258
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HDAC6 inhibition enhances the anti-tumor effect of eribulin through tubulin acetylation in triple-negative breast cancer cells.
    Oba T; Ono M; Matoba H; Uehara T; Hasegawa Y; Ito KI
    Breast Cancer Res Treat; 2021 Feb; 186(1):37-51. PubMed ID: 33452951
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Multi-targeted kinase inhibition alleviates mTOR inhibitor resistance in triple-negative breast cancer.
    He J; McLaughlin RP; van der Noord V; Foekens JA; Martens JWM; van Westen G; Zhang Y; van de Water B
    Breast Cancer Res Treat; 2019 Nov; 178(2):263-274. PubMed ID: 31388935
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of selective cytotoxic and synthetic lethal drug responses in triple negative breast cancer cells.
    Gautam P; Karhinen L; Szwajda A; Jha SK; Yadav B; Aittokallio T; Wennerberg K
    Mol Cancer; 2016 May; 15(1):34. PubMed ID: 27165605
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synergistic antitumor effects of S-1 with eribulin in vitro and in vivo for triple-negative breast cancer cell lines.
    Terashima M; Sakai K; Togashi Y; Hayashi H; De Velasco MA; Tsurutani J; Nishio K
    Springerplus; 2014; 3():417. PubMed ID: 25140293
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synergistic effect of eribulin and CDK inhibition for the treatment of triple negative breast cancer.
    Rao SS; Stoehr J; Dokic D; Wan L; Decker JT; Konopka K; Thomas AL; Wu J; Kaklamani VG; Shea LD; Jeruss JS
    Oncotarget; 2017 Oct; 8(48):83925-83939. PubMed ID: 29137393
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.